Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Gastroenterol Hepatol
    July 2024
  1. CHU CS, Chen HP, Lin PH, Cheng CC, et al
    Interleukin-1 receptor 1 deficiency worsens hepatocellular carcinoma, while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells.
    J Gastroenterol Hepatol. 2024 Jul 15. doi: 10.1111/jgh.16674.
    >> Share

  2. XIN Z, Chen H, Xu J, Zhang H, et al
    Exosomal mRNA in plasma serves as a predictive marker for microvascular invasion in hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jul 7. doi: 10.1111/jgh.16677.
    >> Share

  3. NAKASHIMA R, Kitano Y, Okabe H, Tanizaki T, et al
    Rising pseudocysts in the hepatoduodenal ligament caused by a ruptured intraductal papillary mucinous neoplasm with surgical treatment.
    J Gastroenterol Hepatol. 2024 Jul 1. doi: 10.1111/jgh.16669.
    >> Share

  4. MORI K, Akiyama Y, Tanaka M, Sato T, et al
    Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    J Gastroenterol Hepatol. 2024;39:1382-1393.
    >> Share

  5. MALANDRIS K, Papandreou S, Vasilakou D, Kakotrichi P, et al
    Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.
    J Gastroenterol Hepatol. 2024;39:1219-1229.
    >> Share

  6. LEE RC, Liang PC, Liang HL, Chen YF, et al
    Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN registry.
    J Gastroenterol Hepatol. 2024;39:1318-1327.
    >> Share

  7. SUGITA H, Nakanuma S, Munesue S, Ishikawa T, et al
    Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal obstruction syndrome.
    J Gastroenterol Hepatol. 2024;39:1413-1421.
    >> Share

    June 2024
  8. SUZUKI T, Matsuura K, Suzuki Y, Okumura F, et al
    Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
    J Gastroenterol Hepatol. 2024 Jun 28. doi: 10.1111/jgh.16672.
    >> Share

  9. CHENG J, Yang S, Shou D, Chen J, et al
    FOXO1 induced fatty acid oxidation in hepatic cells by targeting ALDH1L2.
    J Gastroenterol Hepatol. 2024 Jun 25. doi: 10.1111/jgh.16662.
    >> Share

  10. CHATZIPANAGIOTOU OP, Loukas C, Vailas M, Machairas N, et al
    Artificial intelligence in hepatocellular carcinoma diagnosis: a comprehensive review of current literature.
    J Gastroenterol Hepatol. 2024 Jun 23. doi: 10.1111/jgh.16663.
    >> Share

  11. MAUNG ST, Tanpowpong N, Satja M, Treeprasertsuk S, et al
    MRI for hepatocellular carcinoma and the role of abbreviated MRI for surveillance of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jun 20. doi: 10.1111/jgh.16643.
    >> Share

  12. MALIK S, Tenorio BG, Moond V, Dahiya DS, et al
    Systematic review of machine learning models in predicting the risk of bleed/grade of esophageal varices in patients with liver cirrhosis: A comprehensive methodological analysis.
    J Gastroenterol Hepatol. 2024 Jun 17. doi: 10.1111/jgh.16645.
    >> Share

  13. HO CT, Fu CC, Tan EC, Kao WY, et al
    The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy.
    J Gastroenterol Hepatol. 2024 Jun 12. doi: 10.1111/jgh.16640.
    >> Share

  14. WURSTLE S, Schneider T, Karapetyan S, Hapfelmeier A, et al
    LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascites.
    J Gastroenterol Hepatol. 2024 Jun 5. doi: 10.1111/jgh.16637.
    >> Share

  15. LEE KJ, Moon JS, Lim JG, Huh H, et al
    PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children.
    J Gastroenterol Hepatol. 2024;39:1172-1182.
    >> Share

    May 2024
  16. SUN Z, Guo Y, Xu X, Zhou C, et al
    Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway.
    J Gastroenterol Hepatol. 2024 May 28. doi: 10.1111/jgh.16635.
    >> Share

  17. SHIN SK, Oh S, Chun SK, Ahn MJ, et al
    Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 May 27. doi: 10.1111/jgh.16584.
    >> Share

  18. LIU S, Gou H, Wei H, Chen S, et al
    Cholecystohepatic shunt pathway reduces secondary bile acid accumulation to enhance natural killer T cell-mediated anti-hepatocellular carcinoma immunity.
    J Gastroenterol Hepatol. 2024 May 15. doi: 10.1111/jgh.16548.
    >> Share

  19. LIM J, Kim JH, Kim SE, Han SK, et al
    Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort.
    J Gastroenterol Hepatol. 2024 May 8. doi: 10.1111/jgh.16591.
    >> Share

  20. LEE J, Jin YJ, Shin SK, Kwon JH, et al
    Clinical outcomes of transarterial chemoembolization in Child-Turcotte Pugh class A patients with a single small (
    J Gastroenterol Hepatol. 2024 May 6. doi: 10.1111/jgh.16581.
    >> Share

  21. ENDO K, Kakisaka K, Abe T, Yusa K, et al
    Positive impact of obesity on the prognosis of liver cirrhosis.
    J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590.
    >> Share

  22. LEE S, Choi J, Park JH, Lim CY, et al
    Dynamic liver volume change in predicting hepatic decompensation and long-term effects of stereotactic body radiation therapy.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16588.
    >> Share

  23. ZHONG W, Xu B, Lu Y, Chang J, et al
    Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection.
    J Gastroenterol Hepatol. 2024;39:908-919.
    >> Share

  24. PEI X, Jiang W, Li L, Zeng Q, et al
    Mendelian-randomization study revealed causal relationship between nonalcoholic fatty liver disease and osteoporosis/fractures.
    J Gastroenterol Hepatol. 2024;39:847-857.
    >> Share

  25. MAKRI ES, Evripidou K, Polyzos SA
    Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2024;39:806-817.
    >> Share

    April 2024
  26. QI S, Wei X, Zhao J, Wei X, et al
    Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis.
    J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16589.
    >> Share

  27. CAO QH, Liu H, Yan LJ, Wang HC, et al
    Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16558.
    >> Share


  28. Retraction: Rami Al Batran, Fouad Al-Bayaty, Mahmood Ameen Abdulla, Mazen M Jamil Al-Obaidi, Maryam Hajrezaei, Pouya Hassandarvish, Mustafa Fouad, Shahram Golbabapour, Samaneh Talaee. Gastroprotective effects of Corchorus olitorius. J Gastroenterol He
    J Gastroenterol Hepatol. 2024 Apr 26. doi: 10.1111/jgh.16551.
    >> Share

  29. GRYZIAK M, Kraj L, Stec R
    The role of tumor-associated macrophages in hepatocellular carcinoma-from bench to bedside: A review.
    J Gastroenterol Hepatol. 2024 Apr 23. doi: 10.1111/jgh.16564.
    >> Share

  30. LOON E, Narvaez-Barbecho C, Ortiz JP, Balderramo D, et al
    Impact of self-reported ancestry on the epidemiology of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Apr 13. doi: 10.1111/jgh.16578.
    >> Share

  31. LIU Y, Hu Y, Li B, Su R, et al
    Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 Apr 12. doi: 10.1111/jgh.16547.
    >> Share

  32. OHAMA H, Hiraoka A, Tada T, Kariyama K, et al
    Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
    J Gastroenterol Hepatol. 2024 Apr 11. doi: 10.1111/jgh.16553.
    >> Share

  33. CHAN WK, George J
    Metabolic fatty liver syndromes: where do we stand in 2024?
    J Gastroenterol Hepatol. 2024;39:613-614.
    >> Share

  34. PARENTE A, Milana F, Hajibandeh S, Hajibandeh S, et al
    Clinical outcomes after transplantation of domino grafts or standard deceased donor livers: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:620-629.
    >> Share

    March 2024
  35. WANG X, Liu H, Wang Y, Wang P, et al
    Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway.
    J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538.
    >> Share

  36. SUZUKI K, Yasui Y, Tsuchiya K, Matsumoto H, et al
    Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    J Gastroenterol Hepatol. 2024 Mar 17. doi: 10.1111/jgh.16532.
    >> Share

  37. BALE G, Kulkarni AV, Padaki NR, Menon PB, et al
    Comparing rare variants versus common in the pathogenesis of nonalcoholic fatty liver disease: a whole exome sequencing approach.
    J Gastroenterol Hepatol. 2024;39:587-595.
    >> Share

    February 2024
  38. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.
    J Gastroenterol Hepatol. 2024 Feb 29. doi: 10.1111/jgh.16530.
    >> Share


  39. Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis".
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529.
    >> Share

  40. TADA T, Kumada T, Hiraoka A, Kariyama K, et al
    mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16512.
    >> Share

  41. WANG J, Zhang Y, Ma Y, Zhao S, et al
    TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
    >> Share

  42. BATT NM, Rodrigues B, Bloom S, Sawhney R, et al
    Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501.
    >> Share

  43. HAHN JW, Lee H, Shin M, Seong MW, et al
    Diagnostic algorithm for neonatal intrahepatic cholestasis integrating single-gene testing and next-generation sequencing in East Asia.
    J Gastroenterol Hepatol. 2024 Feb 7. doi: 10.1111/jgh.16505.
    >> Share

  44. JI PX, Chen YX, Ni XX, Miao Q, et al
    Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:369-380.
    >> Share

    January 2024
  45. TOYODA H, Tada T, Uojima H, Nozaki A, et al
    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494.
    >> Share

  46. AMJAD W, Jiang Z, Lai M
    Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
    J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495.
    >> Share

  47. DIAO L, Wang C, You R, Leng B, et al
    Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    J Gastroenterol Hepatol. 2024 Jan 19. doi: 10.1111/jgh.16463.
    >> Share

  48. ZHU J, Xia Y, Liu X, Zhang C, et al
    Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489.
    >> Share

  49. NIE MT, Wang PQ, Shi PM, Hong XL, et al
    Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484.
    >> Share

  50. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.
    J Gastroenterol Hepatol. 2024 Jan 11. doi: 10.1111/jgh.16483.
    >> Share

    December 2023
  51. GOPAL P, Banerjee D, Karad A, Dandi K, et al
    Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with cirrhosis of liver.
    J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456.
    >> Share

  52. CHO SH, Song TJ, Oh D, Park DH, et al
    Endoscopic ultrasound-guided hepaticoduodenostomy versus percutaneous drainage for right intrahepatic duct dilatation in malignant hilar obstruction.
    J Gastroenterol Hepatol. 2023 Dec 18. doi: 10.1111/jgh.16442.
    >> Share

  53. TOSHIDA K, Itoh S, Yoshiya S, Nagao Y, et al
    Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Dec 12. doi: 10.1111/jgh.16441.
    >> Share

  54. HUANG X, Zhou LZ, Feng WJ, Liu YQ, et al
    Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic translation
    J Gastroenterol Hepatol. 2023 Dec 7. doi: 10.1111/jgh.16408.
    >> Share

  55. YANG Y, Liu S, Li H, Liu Y, et al
    The protective effect of Nostoc commune Vauch. polysaccharide on alcohol-induced acute alcoholic liver disease and gut microbiota disturbance in mice.
    J Gastroenterol Hepatol. 2023;38:2185-2194.
    >> Share

  56. TONG C, Halengbieke A, Ni X, Han Y, et al
    Bidirectional relationship between nonalcoholic fatty liver disease and serum creatinine-to-body weight ratio as a proxy for skeletal muscle mass index.
    J Gastroenterol Hepatol. 2023;38:2061-2069.
    >> Share

  57. NARANG M, Shah D, Narang S, Gupta N, et al
    Ultrasound-guided aspiration in addition to antibiotics for treatment of liver abscess in children: A randomized controlled trial.
    J Gastroenterol Hepatol. 2023;38:2070-2075.
    >> Share

    November 2023
  58. SHI L, Feng G, Yang X, Zhang Y, et al
    Potential of PAQosome as a therapeutic target for hepatic fibrosis.
    J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427.
    >> Share

  59. DU S, Cao K, Yan Y, Wang Y, et al
    Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16416.
    >> Share

  60. ALLAIRE M, Thabut D
    The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415.
    >> Share

  61. FAROOQ U, Tarar ZI, El Alayli A, Kamal F, et al
    Analyzing the utility of renal replacement therapy to manage hepatorenal syndrome in alcoholic hepatitis without liver transplantation: a nationwide analysis.
    J Gastroenterol Hepatol. 2023 Nov 12. doi: 10.1111/jgh.16388.
    >> Share

  62. SUN J
    Navigating the complex landscape of non-alcoholic fatty liver disease: From genomic associate to the AMPK/mTOR pathways.
    J Gastroenterol Hepatol. 2023;38:1863-1864.
    >> Share

  63. TIAN Y, Wang B
    Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies.
    J Gastroenterol Hepatol. 2023;38:1877-1885.
    >> Share

  64. WANG Y, Huang Y, Zheng T, Sun C, et al
    Gastrointestinal hospitalization during COVID-19 pandemic in the United States: Analysis of a nationwide inpatient sample.
    J Gastroenterol Hepatol. 2023;38:1971-1979.
    >> Share

  65. TAKAHASHI A, Takahata Y, Kokubun M, Anzai Y, et al
    Association between equol and non-alcoholic fatty liver disease in Japanese women in their 50s and 60s.
    J Gastroenterol Hepatol. 2023;38:1958-1962.
    >> Share

  66. MARCONDES-DE-CASTRO IA, Reis-Barbosa PH, Marinho TS, Aguila MB, et al
    AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression.
    J Gastroenterol Hepatol. 2023;38:1868-1876.
    >> Share

    October 2023
  67. QUAN Y, Shou D, Yang S, Cheng J, et al
    Mdivi1 ameliorates mitochondrial dysfunction in non-alcoholic steatohepatitis by inhibiting JNK/MFF signaling.
    J Gastroenterol Hepatol. 2023 Oct 15. doi: 10.1111/jgh.16372.
    >> Share

  68. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    >> Share

  69. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    >> Share

  70. SHOU D, Luo Q, Tang W, Cao C, et al
    Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota.
    J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16359.
    >> Share

  71. ITO T, Morooka H, Takahashi H, Fujii H, et al
    Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
    J Gastroenterol Hepatol. 2023;38:1832-1839.
    >> Share

  72. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle.
    J Gastroenterol Hepatol. 2023;38:1823-1831.
    >> Share

  73. RONG L, Ch'ng D, Jia P, Tsoi KKF, et al
    Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1682-1694.
    >> Share

  74. TAKAHASHI Y, Seko Y, Yamaguchi K, Takeuchi K, et al
    Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2023;38:1743-1749.
    >> Share

    September 2023
  75. KANG SH, Kim MY, Han SK, Baik SK, et al
    Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
    J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327.
    >> Share

  76. HIRATA K, Yamamoto Y, Hatanaka K, Kinoshita K, et al
    Hepatobiliary and pancreatic: Tiny pigmented intra-hepatic ducts stones as the cause of jaundice and liver failure.
    J Gastroenterol Hepatol. 2023 Sep 8. doi: 10.1111/jgh.16350.
    >> Share

  77. GASPAR R, Silva M, Cardoso P, Goncalves R, et al
    Spleen stiffness: a new tool to predict high-risk varices in cirrhotic patients.
    J Gastroenterol Hepatol. 2023 Sep 1. doi: 10.1111/jgh.16344.
    >> Share

  78. MURAKAMI S, Uchida T, Imamura M, Suehiro Y, et al
    Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure.
    J Gastroenterol Hepatol. 2023;38:1637-1646.
    >> Share

  79. HAN E, Chun HS, Lee YH, Lee JS, et al
    MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    J Gastroenterol Hepatol. 2023;38:1598-1609.
    >> Share

    August 2023
  80. HAYASHI H, Sawada K, Tanaka H, Muro K, et al
    The effect of heat-killed Lactobacillus brevis SBL88 on improving selective hepatic insulin resistance in non-alcoholic fatty liver disease mice without altering the gut microbiota.
    J Gastroenterol Hepatol. 2023 Aug 30. doi: 10.1111/jgh.16337.
    >> Share

  81. JIANG H, Xu N, Zhang W, Wei H, et al
    Do gut microbiome-targeted therapies improve liver function in cirrhotic patients? A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023 Aug 15. doi: 10.1111/jgh.16329.
    >> Share

  82. ANIRVAN P
    Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Aug 12. doi: 10.1111/jgh.16328.
    >> Share

  83. KIM K, Lee HW, Ahn SH
    How can we improve surveillance system for alcohol-associated hepatocellular carcinoma?
    J Gastroenterol Hepatol. 2023;38:1203-1204.
    >> Share

  84. CHEN M, Zhong W, Xu W
    Alcohol and the mechanisms of liver disease.
    J Gastroenterol Hepatol. 2023;38:1233-1240.
    >> Share

  85. ZHANG LY, Wang CY, Xu Q, Mu ZQ, et al
    Removal of epigenetic repressive mark on inflammatory genes in fat liver.
    J Gastroenterol Hepatol. 2023;38:1426-1437.
    >> Share

  86. JACOB R, Prince DS, Kench C, Liu K, et al
    Alcohol and its associated liver carcinogenesis.
    J Gastroenterol Hepatol. 2023;38:1211-1217.
    >> Share

  87. VIJAYALEKSHMI B, Choudhary A, Alexander V, Prabhu SB, et al
    Reticuloendothelial activation and phenotypic alteration of peripheral monocytes with enhanced liver recruitment drive liver injury secondary to yellow phosphorus.
    J Gastroenterol Hepatol. 2023;38:1408-1415.
    >> Share

  88. LI R, Liu J, Han P, Shi R, et al
    Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index.
    J Gastroenterol Hepatol. 2023;38:1316-1324.
    >> Share

  89. CHETWOOD JD, Sabih AH, Chan K, Salimi S, et al
    Epidemiology, characteristics, and outcomes of patients with acute-on-chronic liver failure in Australia.
    J Gastroenterol Hepatol. 2023;38:1325-1332.
    >> Share

  90. JEW MH, Hsu CL
    Alcohol, the gut microbiome, and liver disease.
    J Gastroenterol Hepatol. 2023;38:1205-1210.
    >> Share

    July 2023
  91. CHO MS, Lee SK, Kwon JH, Nam SW, et al
    Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis.
    J Gastroenterol Hepatol. 2023 Jul 10. doi: 10.1111/jgh.16277.
    >> Share

  92. CHOI WM, Yoo SY, Chang JI, Han S, et al
    A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization.
    J Gastroenterol Hepatol. 2023 Jul 7. doi: 10.1111/jgh.16280.
    >> Share

  93. LIU X, Wang J, Li M, Qiu J, et al
    Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis.
    J Gastroenterol Hepatol. 2023 Jul 6. doi: 10.1111/jgh.16279.
    >> Share

  94. PODDAR U, Samanta A, Sarma MS, Kumar B, et al
    How to suspect the presence of high-risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
    J Gastroenterol Hepatol. 2023 Jul 5. doi: 10.1111/jgh.16267.
    >> Share

  95. CHENG HY, Hu RH, Hsiao CY, Ho MC, et al
    Hepatitis C treatment and long-term outcome of patients with hepatocellular carcinoma after resection.
    J Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1111/jgh.16276.
    >> Share

  96. LIU M, Qiu H, Zhang W, Mei T, et al
    Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1018-1027.
    >> Share

  97. LIU P, Yao L, Hu X, Wang Z, et al
    Recent advances in the immunomodulation mechanism of mesenchymal stem cell therapy in liver diseases.
    J Gastroenterol Hepatol. 2023;38:1099-1106.
    >> Share

  98. SHEN J, Cao J, Chen M, Zhang Y, et al
    Recent advances in the role of exosomes in liver fibrosis.
    J Gastroenterol Hepatol. 2023;38:1083-1088.
    >> Share

  99. SEDAROUS M, Youssef M, Adekunle AD, Babajide O, et al
    A nationwide study of liver disease hospitalizations during the coronavirus pandemic in the United States.
    J Gastroenterol Hepatol. 2023;38:1148-1157.
    >> Share

  100. JIANG N, Xiao Y, Yuan K, Wang Z, et al
    Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.
    J Gastroenterol Hepatol. 2023;38:1056-1071.
    >> Share

    June 2023
  101. MINORETTI P, Emanuele E
    Reversing nonalcoholic fatty liver disease-related cirrhosis by inhibiting pyruvate kinase M2: a role for shikonin?
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16273.
    >> Share

  102. SHARMA BC, Maharshi S, Sachdeva S, Mahajan B, et al
    Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double-blind randomized controlled trial.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16266.
    >> Share

  103. GIRI S, Singh A, Kolhe K, Kale A, et al
    Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis.
    J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16263.
    >> Share

  104. LIU J, Man K
    Biomarkers for monitoring alcohol sobriety after liver transplantation for alcoholic liver disease.
    J Gastroenterol Hepatol. 2023 Jun 23. doi: 10.1111/jgh.16269.
    >> Share

  105. SUZUKI Y, Maekawa S, Yamashita K, Osawa L, et al
    Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
    J Gastroenterol Hepatol. 2023;38:921-929.
    >> Share

  106. ISHIBA H, Sumida Y, Kamada Y, Fujii H, et al
    Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
    J Gastroenterol Hepatol. 2023;38:896-904.
    >> Share

    May 2023
  107. TADA T, Kumada T, Hiraoka A, Hirooka M, et al
    Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 May 25. doi: 10.1111/jgh.16225.
    >> Share

  108. DONG Y, Liu Y, Liu X, Ma H, et al
    Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures.
    J Gastroenterol Hepatol. 2023 May 24. doi: 10.1111/jgh.16221.
    >> Share

  109. WU CW, Wong GL, Wong VW, Yam TF, et al
    Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.
    J Gastroenterol Hepatol. 2023 May 22. doi: 10.1111/jgh.16218.
    >> Share

  110. ZHOU F, Mai T, Wang Z, Zeng Z, et al
    The improvement of intestinal dysbiosis and hepatic metabolic dysfunction in dextran sulfate sodium-induced colitis mice: effects of curcumin.
    J Gastroenterol Hepatol. 2023 May 20. doi: 10.1111/jgh.16205.
    >> Share

  111. KIM DS, Kim BK, Lee JS, Lee HW, et al
    Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis.
    J Gastroenterol Hepatol. 2023 May 15. doi: 10.1111/jgh.16210.
    >> Share

  112. AHMED Z, Badal J, Nawras M, Battepati D, et al
    Role of rifaximin in the management of alcohol-associated hepatitis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:703-709.
    >> Share

  113. SHIRAKAMI Y, Kato J, Maeda T, Ideta T, et al
    Skeletal muscle atrophy is exacerbated by steatotic and fibrotic liver-derived TNF-alpha in senescence-accelerated mice.
    J Gastroenterol Hepatol. 2023;38:800-808.
    >> Share

    April 2023
  114. VERMA N, Vojjala N, Mishra S, Valsan A, et al
    Machine learning can guide suitability of consultation and patient referral through telemedicine for hepatobiliary diseases.
    J Gastroenterol Hepatol. 2023 Apr 28. doi: 10.1111/jgh.16194.
    >> Share

  115. ALABBAS SY, Giri R, Oancea I, Davies J, et al
    Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver.
    J Gastroenterol Hepatol. 2023;38:609-618.
    >> Share

    March 2023
  116. MURATA K, Mizokami M
    Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Mar 14. doi: 10.1111/jgh.16178.
    >> Share

  117. MAO S, Liu Q, Wu H, Zhu J, et al
    Phase separation of YAP mediated by CC domain promotes hepatoblastoma proliferation via activation of transcription.
    J Gastroenterol Hepatol. 2023 Mar 12. doi: 10.1111/jgh.16173.
    >> Share

  118. MOU L, Li K, Xu C, Xu I, et al
    Construction of Endothelial Cell- and Autophagy-Related Prognostic Models for Hepatocellular Carcinoma Based on Single-Cell Data.
    J Gastroenterol Hepatol. 2023 Mar 9. doi: 10.1111/jgh.16172.
    >> Share

  119. TSUMURA S, Shimose S, Niizeki T, Kuboyama E, et al
    Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.
    J Gastroenterol Hepatol. 2023 Mar 7. doi: 10.1111/jgh.16168.
    >> Share

  120. MNATZAGANIAN G, MacLachlan JH, Allard N, Brown C, et al
    Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16162.
    >> Share

  121. BOUSTANY A, Onwuzo S, Zeid HKA, Almomani A, et al
    Non-alcoholic steatohepatitis is independently associated with a history of gestational diabetes mellitus.
    J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16163.
    >> Share

  122. WONG GL
    Editorial: Appraising liver fibrosis with eagle eyes.
    J Gastroenterol Hepatol. 2023;38:343.
    >> Share

  123. CHEN Q, Guo J, Qiu T, Zhou J, et al
    Mechanism of ASK1 involvement in liver diseases and related potential therapeutic targets: A critical pathway molecule worth investigating.
    J Gastroenterol Hepatol. 2023;38:378-385.
    >> Share

  124. ZHAO Q, Liang L, Zhai F, Ling G, et al
    A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022.
    J Gastroenterol Hepatol. 2023;38:359-369.
    >> Share

    February 2023
  125. DUNNE CL, Kaur S, Delacruz B, Bresee LC, et al
    30-day Readmission Rates Among Upper Gastrointestinal Bleeds: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2023 Feb 20. doi: 10.1111/jgh.16153.
    >> Share

  126. ZHAO X, Shi X, Gu H, Zhou W, et al
    Association between handgrip strength, nonalcoholic fatty liver disease, advanced hepatic fibrosis and its modifiers: evidence from the NHANES database of the US.
    J Gastroenterol Hepatol. 2023 Feb 18. doi: 10.1111/jgh.16150.
    >> Share

  127. MORAN-RAMOS S, Cerqueda-Garcia D, Lopez-Contreras B, Larrieta-Carrasco E, et al
    A metagenomic study identifies a Prevotella-copri enriched microbial profile associated with non-alcoholic steatohepatitis in subjects with obesity.
    J Gastroenterol Hepatol. 2023 Feb 17. doi: 10.1111/jgh.16147.
    >> Share

  128. AAMANN L, Dam G, Jepsen P, Borre M, et al
    Reduced three-year risk of hospital admission and mortality after 12-weeks resistance training of cirrhosis patients - a follow-up of a randomized clinical trial.
    J Gastroenterol Hepatol. 2023 Feb 5. doi: 10.1111/jgh.16141.
    >> Share

  129. NOGAMI A, Iwaki M, Kobayashi T, Honda Y, et al
    Real-world assessment of SmartExam, a novel FibroScan computational method: A retrospective single-center cohort study.
    J Gastroenterol Hepatol. 2023;38:321-329.
    >> Share

  130. MOHR I, Bourhis H, Woimant F, Obadia MA, et al
    Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl.
    J Gastroenterol Hepatol. 2023;38:219-224.
    >> Share

    January 2023
  131. CHO SH, Song TJ, Park JS, Yoon JH, et al
    Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: a multicenter cohort study.
    J Gastroenterol Hepatol. 2023 Jan 29. doi: 10.1111/jgh.16136.
    >> Share

  132. LEE HA, Lee YS, Jung YK, Kim JH, et al
    Antiviral therapy does not improve outcomes of patients with HBV-related decompensated cirrhosis and undetectable DNA.
    J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16132.
    >> Share

  133. BHATEJA A, Bodh V, Chauhan A
    Role of Nutrition in the management of hepatic encephalopathy - Do we know all?
    J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16131.
    >> Share

  134. ZHANG Q, Jia R, Chen M, Wang J, et al
    Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and HSCs.
    J Gastroenterol Hepatol. 2023 Jan 18. doi: 10.1111/jgh.16126.
    >> Share

  135. JANG W, Lee HW
    Hepatobiliary and Pancreatic: Hepatic mass discovered incidentally with telangiectasia.
    J Gastroenterol Hepatol. 2023 Jan 17. doi: 10.1111/jgh.16094.
    >> Share

  136. ABASSERI M, Hoque S, Kochovska S, Caldwell K, et al
    Barriers to Palliative Care in Hepatocellular Carcinoma: A Review of the Literature.
    J Gastroenterol Hepatol. 2023 Jan 12. doi: 10.1111/jgh.16107.
    >> Share

    December 2022
  137. KAZANKOV K, Nixon-Hill M, Kumar R, Amin A, et al
    A novel Smartphone scleral-image based tool for assessing jaundice in decompensated cirrhosis patients.
    J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16093.
    >> Share

  138. LEE WS, Arai K, Alex G, Treepongkaruna S, et al
    Medical Management of Pediatric Inflammatory Bowel Disease (PIBD) in the Asia Pacific Region: A Position Paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group.
    J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16097.
    >> Share

  139. AHUJA H, Sharma BC, Sachdeva S, Mahajan B, et al
    A double blind Randomized Controlled Trial to assess efficacy of Nutritional Therapy for prevention of recurrence of Hepatic Encephalopathy in patients with Cirrhosis.
    J Gastroenterol Hepatol. 2022 Dec 27. doi: 10.1111/jgh.16096.
    >> Share

  140. LONG Y, Song X, Guan Y, Lan R, et al
    Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2022 Dec 14. doi: 10.1111/jgh.16088.
    >> Share

  141. LEE WS, Arai K, Alex G, Treepongkaruna S, et al
    Management and Monitoring of Pediatric Inflammatory Bowel Disease (PIBD) in the Asia Pacific Region: A Position Paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical M
    J Gastroenterol Hepatol. 2022 Dec 12. doi: 10.1111/jgh.16084.
    >> Share

  142. YOSHIDA S, Minaga K, Watanabe T, Kudo M, et al
    Hepatobiliary and Pancreatic: Multiple pancreatic masses with rich vascularity.
    J Gastroenterol Hepatol. 2022 Dec 5. doi: 10.1111/jgh.16060.
    >> Share

  143. SEKO Y, Kawanaka M, Fujii H, Iwaki M, et al
    Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
    J Gastroenterol Hepatol. 2022;37:2313-2320.
    >> Share

    November 2022
  144. KARAGIANNAKIS DS, Voulgaris T, Markakis G, Lakiotaki D, et al
    Spleen stiffness can predict liver decompensation and survival in patients with cirrhosis.
    J Gastroenterol Hepatol. 2022 Nov 8. doi: 10.1111/jgh.16057.
    >> Share

  145. OUYANG R, Li H, Tan W, Wang X, et al
    Portal vein thrombosis compromises the performance of MELD and MELD-Na scores in patients with cirrhosis.
    J Gastroenterol Hepatol. 2022 Nov 7. doi: 10.1111/jgh.16053.
    >> Share

  146. ALMOMANI A, Kumar P, Onwuzo S, Boustany A, et al
    Epidemiology and Prevalence of Lean Non-Alcoholic Fatty Liver Disease and Associated Cirrhosis, HCC and Cardiovascular Outcomes in the United States: A Population-Based Study and Review of Literature.
    J Gastroenterol Hepatol. 2022 Nov 3. doi: 10.1111/jgh.16049.
    >> Share

  147. HAKODA H, Kiritani S, Kokudo T, Yoshimura K, et al
    Probe electrospray ionization mass spectrometry-based rapid diagnosis of liver tumors.
    J Gastroenterol Hepatol. 2022;37:2182-2188.
    >> Share

    October 2022
  148. YANG Z, Wan W, Zhang P, Wang S, et al
    Crosstalk between heat shock factor 1 and signal transducer and activator of transcription 3 mediated by interleukin-8 autocrine signaling maintains the cancer stem cell phenotype in liver cancer.
    J Gastroenterol Hepatol. 2022 Oct 27. doi: 10.1111/jgh.16040.
    >> Share

  149. GORGANI F, Esfahani Z, Ghamari SH, Ghasemi E, et al
    Global, Regional, and National Burden and Quality of Care Index of Liver Cirrhosis by Cause from Global Burden of Disease 1990-2019.
    J Gastroenterol Hepatol. 2022 Oct 26. doi: 10.1111/jgh.16041.
    >> Share

  150. MEENA BL, Taneja S, Tandon P, Sahni N, et al
    Home-based Intensive Nutrition Therapy improves Frailty and Sarcopenia in Patients with Decompensated Cirrhosis: A Randomized Clinical Trial.
    J Gastroenterol Hepatol. 2022 Oct 21. doi: 10.1111/jgh.16035.
    >> Share

  151. LIU Y, Chen M
    Targeting hepatic stellate cells may serve as a promising target for hepatic steatosis.
    J Gastroenterol Hepatol. 2022 Oct 18. doi: 10.1111/jgh.16028.
    >> Share

  152. SARAIVA RO, Gamelas V, Canha MI, Carvalho D, et al
    Hepatobiliary and Pancreatic: An unusual cause of biliary obstruction.
    J Gastroenterol Hepatol. 2022 Oct 10. doi: 10.1111/jgh.16009.
    >> Share

  153. HOU G, Xu W, Ding D, Tian T, et al
    Metabolome and Transcriptome Integration Reveals Metabolic Profile of Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2022 Oct 8. doi: 10.1111/jgh.16024.
    >> Share

  154. FERNANDEZ M, Lokan J, Leung C, Grigg A, et al
    A critical evaluation of the role of iron overload in fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1873-1883.
    >> Share

  155. LIN CL, Tai CM, Huang JF, Liu CJ, et al
    The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    J Gastroenterol Hepatol. 2022;37:1901-1910.
    >> Share

  156. TONTIKIDOU C, Makri ES, Evripidou K, Goulis DG, et al
    Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2022;37:1853-1864.
    >> Share

    September 2022
  157. ZHANG C, Dai D, Zhang W, Yang W, et al
    Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 Sep 6. doi: 10.1111/jgh.15999.
    >> Share

  158. LIM SZ, Chuah KH, Rajaram RB, Stanley K, et al
    Epidemiological trends of gastrointestinal and liver diseases in Malaysia: A single-center observational study.
    J Gastroenterol Hepatol. 2022;37:1732-1740.
    >> Share

  159. JEE JJ, Lim J, Park S, Koh H, et al
    Gut microbial community differentially characterizes patients with nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1822-1832.
    >> Share

  160. INADA K, Tamaki N, Kurosaki M, Kirino S, et al
    Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1726-1731.
    >> Share

    August 2022
  161. PRINCE DS, Schlaphoff G, Davison SA, Huo YR, et al
    Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study.
    J Gastroenterol Hepatol. 2022 Aug 28. doi: 10.1111/jgh.15986.
    >> Share

  162. KAWAHARA A, Kanno K, Yonezawa S, Otani Y, et al
    Depletion of hepatic stellate cells inhibits hepatic steatosis in mice.
    J Gastroenterol Hepatol. 2022 Aug 6. doi: 10.1111/jgh.15974.
    >> Share

  163. POHL K, Moodley P, Dhanda A
    The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: A systematic review.
    J Gastroenterol Hepatol. 2022;37:1498-1506.
    >> Share

  164. ZHANG H, Wang Y, Chen C, Wang B, et al
    Non-alcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes.
    J Gastroenterol Hepatol. 2022;37:1633-1640.
    >> Share

  165. HA Y, Chon YE, Kim MN, Lee JH, et al
    Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1624-1632.
    >> Share

  166. KIM HJ, Park SJ, Park HK, Byun DW, et al
    Association of thyroid autoimmunity with nonalcoholic fatty liver disease in euthyroid middle-aged subjects: A population-based study.
    J Gastroenterol Hepatol. 2022;37:1617-1623.
    >> Share

    July 2022
  167. BINET Q, Annet L, Danse E, Goffette P, et al
    Hepatobiliary and Pancreatic: An uncommon cause of portal hypertension.
    J Gastroenterol Hepatol. 2022 Jul 28. doi: 10.1111/jgh.15961.
    >> Share

  168. LEE H, Kim BK
    Real-world clinical features, healthcare utilization, and economic burden in decompensated cirrhosis patients; a national database.
    J Gastroenterol Hepatol. 2022 Jul 21. doi: 10.1111/jgh.15962.
    >> Share

  169. FENG G, He N, Xia HH, Mi M, et al
    Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 Jul 11. doi: 10.1111/jgh.15940.
    >> Share

  170. UFUK F, Aykota MR
    Hepatobiliary and Pancreatic: Todani type I choledochal cyst and cystic malformation of the cystic duct.
    J Gastroenterol Hepatol. 2022 Jul 6. doi: 10.1111/jgh.15931.
    >> Share

  171. LONARDO A
    Precision medicine in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1175-1178.
    >> Share

  172. GIRI S, Agarwal D, Afzalpurkar S
    GGT dynamic for advanced fibrosis in NAFLD: Novel but not convincing.
    J Gastroenterol Hepatol. 2022;37:1406.
    >> Share

    June 2022
  173. KAKIZOE M, Nagata K, Sasaki R, Ozawa E, et al
    Hepatobiliary and Pancreatic: Ruptured pseudoaneurysm after endoscopic biliary stenting using the novel double-pit-type plastic stent.
    J Gastroenterol Hepatol. 2022 Jun 27. doi: 10.1111/jgh.15913.
    >> Share

  174. LIU J, Qian Y, Yang F, Huang S, et al
    Value of prediction-model in distinguishing gallbladder adenoma from cholesterol polyp.
    J Gastroenterol Hepatol. 2022 Jun 24. doi: 10.1111/jgh.15928.
    >> Share

  175. LIU H, Yang XL, Dong ZR, Chen ZQ, et al
    Clinical Benefits of Direct-acting Antivirals Therapy in Hepatitis C Virus Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    J Gastroenterol Hepatol. 2022 Jun 20. doi: 10.1111/jgh.15915.
    >> Share

  176. WONG YJ, Li J, Liu C, Chen Z, et al
    CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
    J Gastroenterol Hepatol. 2022;37:1043-1051.
    >> Share

    May 2022
  177. DUNN W, Song X, Koestler D, Grdinovac K, et al
    Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
    J Gastroenterol Hepatol. 2022 May 25. doi: 10.1111/jgh.15900.
    >> Share

  178. CHAN SL, Wong N, Lam WKJ, Kuang M, et al
    Personalized treatment for hepatocellular carcinoma: Current status and Future perspectives.
    J Gastroenterol Hepatol. 2022 May 15. doi: 10.1111/jgh.15889.
    >> Share

  179. TENG PC, Agopian VG, Lin TY, You S, et al
    Circulating tumor cells: a step toward precision medicine in hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2022 May 11. doi: 10.1111/jgh.15886.
    >> Share

  180. CHOI AY, Kolb J, Shah S, Chahine A, et al
    Endoscopic ultrasound-guided portal pressure gradient with liver biopsy: 6 years of endo-hepatology in practice.
    J Gastroenterol Hepatol. 2022 May 5. doi: 10.1111/jgh.15875.
    >> Share

  181. WANG X, Gao X, Wu R, Chi X, et al
    Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
    J Gastroenterol Hepatol. 2022 May 4. doi: 10.1111/jgh.15881.
    >> Share

    April 2022
  182. SHINKAI K, Sakamori R, Yamada R, Tahata Y, et al
    Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
    J Gastroenterol Hepatol. 2022 Apr 17. doi: 10.1111/jgh.15853.
    >> Share

  183. SATO M, Kobayashi T, Soroida Y, Tanaka T, et al
    Development of novel deep multimodal representation learning-based model for the differentiation of liver tumors on B-mode ultrasound images.
    J Gastroenterol Hepatol. 2022;37:678-684.
    >> Share

  184. SASAKI Y, Abe Y, Nishise S, Yagi M, et al
    Low serum pancreatic amylase levels as a novel latent risk factor for colorectal adenoma in non-alcohol drinkers.
    J Gastroenterol Hepatol. 2022;37:660-668.
    >> Share

    March 2022
  185. LEUNG HH, Puspanathan P, Chan AW, Mustapha NRN, et al
    Reliability of the Nonalcoholic Steatohepatitis Clinical Research Network and Steatosis Activity Fibrosis histological scoring systems.
    J Gastroenterol Hepatol. 2022 Mar 31. doi: 10.1111/jgh.15843.
    >> Share

  186. HUANG X, Zhu L, Wang L, Huang W, et al
    YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation.
    J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15816.
    >> Share

  187. OGAWA Y, Nakahara T, Ono M, Kawaguchi T, et al
    Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease.
    J Gastroenterol Hepatol. 2022;37:592-599.
    >> Share

  188. HUSSAIN I, Wong YJ, Lohan R, Lin S, et al
    Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials.
    J Gastroenterol Hepatol. 2022;37:455-463.
    >> Share

  189. YANG W, Yusufu Y, Wang C
    Gastrointestinal: A rare case of upper gastrointestinal bleeding: Splenosis mimicking gastric varices.
    J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15795.
    >> Share

    February 2022
  190. LIU Y, Liu S, Huang J, Zhu Y, et al
    Validation of five hepatic steatosis algorithms in metabolic- associated fatty liver disease: a population based study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15799.
    >> Share

  191. MUNDADA K, Goel A, Paliwal VK, Singh TP, et al
    Short course of low-dose pregabalin is effective for the treatment of restless leg syndrome in patients with cirrhosis: A pilot study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15803.
    >> Share

  192. KEMP W, Clayton-Chubb D, Majeed A, Glenister KM, et al
    Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    J Gastroenterol Hepatol. 2022;37:395-403.
    >> Share

  193. BE KH, Zorron Cheng Tao Pu L, Apostolov R, Vaughan R, et al
    Gastrointestinal: Gastric variceal coil migration: A rare entity in endoscopy.
    J Gastroenterol Hepatol. 2022;37:281.
    >> Share

    January 2022
  194. YUAN BH, Li RH, Huo RR, Li MJ, et al
    Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
    J Gastroenterol Hepatol. 2022 Jan 26. doi: 10.1111/jgh.15783.
    >> Share

  195. CHAN WK, Tan SS, Chan SP, Lee YY, et al
    The Malaysian Society of Gastroenterology and Hepatology Consensus Statement on Metabolic Dysfunction-Associated Fatty Liver Disease.
    J Gastroenterol Hepatol. 2022 Jan 25. doi: 10.1111/jgh.15787.
    >> Share

  196. MOLLER S, Henriksen JH, Sjostedt S, Bendtsen F, et al
    Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis.
    J Gastroenterol Hepatol. 2022 Jan 11. doi: 10.1111/jgh.15778.
    >> Share

  197. YU J
    The functional role and translational potential of gut microbiota and microbial metabolites in liver diseases.
    J Gastroenterol Hepatol. 2022;37:5-6.
    >> Share

  198. LI M, Rajani C, Zheng X, Jia W, et al
    The microbial metabolome in metabolic-associated fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:15-23.
    >> Share

  199. SUK KT, Koh H
    New perspective on fecal microbiota transplantation in liver diseases.
    J Gastroenterol Hepatol. 2022;37:24-33.
    >> Share

  200. PAN Y, Zhang X
    Diet and gut microbiome in fatty liver and its associated liver cancer.
    J Gastroenterol Hepatol. 2022;37:7-14.
    >> Share

    December 2021
  201. AHN HS, Kim HJ, Kang TU, Park SM, et al
    Cholecystectomy reduces the risk of cholangiocarcinoma in patients with complicated gallstones, but has negligible effect on hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Dec 14. doi: 10.1111/jgh.15759.
    >> Share

  202. KERR CJ, Waterworth SP, Brodie D, Sandercock GRH, et al
    The associations between physical activity intensity, cardiorespiratory fitness, and non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3508-3514.
    >> Share

  203. PAN J, Cen L, Zhou T, Yu M, et al
    Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3438-3447.
    >> Share

  204. HUANG H, Hou J, Liu K, Liu Q, et al
    RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
    J Gastroenterol Hepatol. 2021;36:3429-3437.
    >> Share

  205. SATO Y, Yoneda A, Shimizu F, Nishimura M, et al
    Resolution of fibrosis by siRNA HSP47 in vitamin A-coupled liposomes induces regeneration of chronically injured livers.
    J Gastroenterol Hepatol. 2021;36:3418-3428.
    >> Share

  206. ZHU Z, Yin J, Dawsey SM, Liu B, et al
    Association between serum ferritin, incident primary liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: A nested case-control study.
    J Gastroenterol Hepatol. 2021;36:3410-3417.
    >> Share

    November 2021
  207. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
    Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
    J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.
    >> Share

  208. KIM BH, Yu SJ, Kang W, Cho SB, et al
    Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
    >> Share

  209. POTOUPNI V, Georgiadou M, Chatzigriva E, Polychronidou G, et al
    Circulating tumor necrosis factor-alpha levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2021;36:3002-3014.
    >> Share

  210. LEE S, Kim KW, Lee J, Park T, et al
    Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors.
    J Gastroenterol Hepatol. 2021;36:3212-3218.
    >> Share

  211. KUCHAY MS, Choudhary NS, Gagneja S, Mathew A, et al
    Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3204-3211.
    >> Share

    October 2021
  212. LE TV, Dinh NBT, Dang MT, Phan NCL, et al
    THE EFFECTS OF AUTOPHAGY INHIBITION BY CHLOROQUINE ON HEPATIC STELLATE CELL ACTIVATION IN CCl4 -INDUCED ACUTE LIVER INJURY MOUSE MODEL.
    J Gastroenterol Hepatol. 2021 Oct 28. doi: 10.1111/jgh.15726.
    >> Share

  213. CHANG WI, Kim BH, Kim YJ, Yoon JH, et al
    The role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
    J Gastroenterol Hepatol. 2021 Oct 24. doi: 10.1111/jgh.15722.
    >> Share

  214. NAKATSU G
    Toward a postbiotic era of microbiome science: opportunities to advance immunotherapies for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Oct 19. doi: 10.1111/jgh.15715.
    >> Share

  215. CHEN T, Zhou K, Sun T, Sang C, et al
    Bile acid glycine:taurine ratios predict the progression of chronic liver disease.
    J Gastroenterol Hepatol. 2021 Oct 16. doi: 10.1111/jgh.15709.
    >> Share

  216. HUO TI, Ho SY, Liao JI
    Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role?
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15707.
    >> Share

  217. YIM HJ, Kim W, Ahn SH, Jung YK, et al
    Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15710.
    >> Share

  218. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
    Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
    J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
    >> Share

  219. TAMAKI N, Kurosaki M, Takahashi Y, Itakura Y, et al
    Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.
    J Gastroenterol Hepatol. 2021;36:2960-2966.
    >> Share

  220. CHEN TP, Lin WY, Chiang CH, Shen TH, et al
    Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat.
    J Gastroenterol Hepatol. 2021;36:2903-2910.
    >> Share

  221. HU HT, Wang W, Chen LD, Ruan SM, et al
    Artificial intelligence assists identifying malignant versus benign liver lesions using contrast-enhanced ultrasound.
    J Gastroenterol Hepatol. 2021;36:2875-2883.
    >> Share

  222. RODRIGUEZ-ANTONIO I, Lopez-Sanchez GN, Uribe M, Chavez-Tapia NC, et al
    Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:2720-2727.
    >> Share

  223. WANG Y, Liu Y
    Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell.
    J Gastroenterol Hepatol. 2021;36:2706-2714.
    >> Share

    September 2021
  224. LI R, Ong Q, Wong CC, Chu ES, et al
    O-GlcNAcylation inhibits hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2021 Sep 21. doi: 10.1111/jgh.15690.
    >> Share

  225. LOCKART I, Hajarizadeh B, Buckley N, Davison S, et al
    All cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
    J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687.
    >> Share

  226. YADA S, Sasaki S, Tokuno K, Yamashita Y, et al
    Hepatobiliary and Pancreatic: Extramammary Paget disease of the esophagus.
    J Gastroenterol Hepatol. 2021 Sep 2. doi: 10.1111/jgh.15665.
    >> Share

  227. PENNISI G, Di Marco V, Buscemi C, Mazzola G, et al
    Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population.
    J Gastroenterol Hepatol. 2021;36:2389-2396.
    >> Share

  228. CHEN D, Zeng R, Teng G, Cai C, et al
    Menstrual blood-derived mesenchymal stem cells attenuate inflammation and improve the mortality of acute liver failure combining with A2AR agonist in mice.
    J Gastroenterol Hepatol. 2021;36:2619-2627.
    >> Share

    August 2021
  229. ZHAO D, Xia L, Geng W, Xu D, et al
    Metformin suppresses IL-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
    J Gastroenterol Hepatol. 2021 Aug 25. doi: 10.1111/jgh.15674.
    >> Share

  230. EMORI T, Nuta J, Kawaji Y, Tamura T, et al
    Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: a prospective study.
    J Gastroenterol Hepatol. 2021 Aug 16. doi: 10.1111/jgh.15661.
    >> Share

  231. OGAWA E, Nakamuta M, Furusyo N, Kajiwara E, et al
    Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs.
    J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659.
    >> Share

  232. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.
    >> Share

  233. CHEN M, Hu G, Zhou X, Peng Z, et al
    Hsa_circ_0016788 regulates glycolysis and proliferation via miR-506-3p/PARP14 axis of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Aug 2. doi: 10.1111/jgh.15635.
    >> Share

  234. TAHER MK, Crispo JAG, Fortin Y, Moog R, et al
    Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.
    J Gastroenterol Hepatol. 2021;36:2307-2314.
    >> Share

  235. CHEN H, Johnston A, Palmer A, Mickenbecker M, et al
    Too little, too late: Palliation and end-stage liver disease.
    J Gastroenterol Hepatol. 2021;36:2303-2306.
    >> Share

    July 2021
  236. MAK J, Chan SM, Siu B, Lai J, et al
    Hepatobiliary and Pancreatic: A tree in the liver.
    J Gastroenterol Hepatol. 2021 Jul 27. doi: 10.1111/jgh.15623.
    >> Share

  237. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    >> Share

  238. SHI M, Sheng L, Lian M, Miao Q, et al
    Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15629.
    >> Share

  239. WU L, Huang XQ, Li N, Xie C, et al
    An MRI Modality for Non-invasively Distinguishing Progression of Liver Fibrosis by Visualizing Hepatic Platelet-Derived Growth Factor Receptor-Beta Expression in Mice.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15628.
    >> Share

  240. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.
    >> Share

  241. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    >> Share

  242. LIU CH, Ampuero J, Pavlides M, Wong VW, et al
    Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1754-1768.
    >> Share

  243. KANG HT, Jang K, Jun DW, Yoon EL, et al
    Macro-encapsulation of mesenchymal stem cells in acute and chronic liver injury animal models.
    J Gastroenterol Hepatol. 2021;36:1997-2007.
    >> Share

  244. KULKARNI AV, Anand L, Vyas AK, Premkumar M, et al
    Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial.
    J Gastroenterol Hepatol. 2021;36:1953-1961.
    >> Share

  245. NISHIKAWA M, Kinoshita M, Morimoto Y, Ishikiriyama T, et al
    Lipopolysaccharide preconditioning reduces liver metastasis of Colon26 cells by enhancing antitumor activity of natural killer cells and natural killer T cells in murine liver.
    J Gastroenterol Hepatol. 2021;36:1889-1898.
    >> Share

  246. YAMAMOTO K, Ikeya T, Okuyama S, Fukuda K, et al
    The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development.
    J Gastroenterol Hepatol. 2021;36:1971-1978.
    >> Share

    June 2021
  247. COUPER MR, Chennapragada M, Magoffin A
    Hepatobiliary and Pancreatic: A rare peribiliary lesion.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15556.
    >> Share

  248. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    >> Share

  249. HO SY, Liu PH, Hsu CY, Ko CC, et al
    Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    J Gastroenterol Hepatol. 2021 Jun 22. doi: 10.1111/jgh.15593.
    >> Share

  250. PHRUEKSOTSAI S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al
    Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15580.
    >> Share

  251. FAJARDO J, Nunez E, Szafranska J, Poca M, et al
    We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection.
    J Gastroenterol Hepatol. 2021 Jun 9. doi: 10.1111/jgh.15537.
    >> Share

  252. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    >> Share

  253. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
    Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1470-1478.
    >> Share

  254. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
    J Gastroenterol Hepatol. 2021;36:1497-1507.
    >> Share

  255. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    >> Share

  256. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    >> Share

  257. LIU D, Shen Y, Zhang R, Xun J, et al
    Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    J Gastroenterol Hepatol. 2021;36:1670-1678.
    >> Share

  258. HUANG Y, Huang F, Yang L, Hu W, et al
    Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
    J Gastroenterol Hepatol. 2021;36:1562-1570.
    >> Share

  259. YIP TC, Wong VW, Wong GL
    Liver-heart connection in diabetes mellitus.
    J Gastroenterol Hepatol. 2021;36:1385-1386.
    >> Share

    May 2021
  260. ZHOU J, Wang C, Chen Z
    Hepatobiliary and Pancreatic: Castleman disease of the pancreas diagnosed by endoscopic ultrasound.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15520.
    >> Share

  261. KANEKO S, Kurosaki M, Inada K, Kirino S, et al
    Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15563.
    >> Share

  262. AGARWAL S, Sharma S, Kumar M, Venishetty S, et al
    Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept.
    J Gastroenterol Hepatol. 2021 May 28. doi: 10.1111/jgh.15560.
    >> Share

  263. MA HL, Chen SD, Zheng KI, Yu Y, et al
    The TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15554.
    >> Share

  264. TAK KY, Jang B, Lee SK, Nam HC, et al
    The prognostic role of M2BPGi compared with the HAP score in hepatocellular carcinoma patients receiving transarterial treatment.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15553.
    >> Share

  265. ZHAO JA, Nie W, Dong L, Liu W, et al
    A curcumin analogue GL63 inhibits the malignant behaviors of hepatocellular carcinoma by inactivating the JAK2/STAT3 signaling pathway via the circZNF83/miR-324-5p/CDK16 axis.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15545.
    >> Share

  266. CHANG H, Li J, Luo Y, Wu B, et al
    TFB2M activates aerobic glycolysis in hepatocellular carcinoma cells through the NAD(+) /SIRT3/HIF-1alpha signaling.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15548.
    >> Share

  267. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    >> Share

  268. XIE JM, Liu JH, Sun YH, Li W, et al
    Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.
    J Gastroenterol Hepatol. 2021 May 9. doi: 10.1111/jgh.15518.
    >> Share

  269. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    >> Share

  270. CHEN Z, Jiang H, Wang Y, Liang R, et al
    Three-day Postoperative Antibiotics Reduces Post-hepatectomy Infection Rate in HBV-related Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 May 4. doi: 10.1111/jgh.15528.
    >> Share

  271. ANAND A, Elhence A, Vaishnav M, Singh AA, et al
    FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
    J Gastroenterol Hepatol. 2021;36:1309-1316.
    >> Share

  272. LI X, Qin P, Cao L, Lou Y, et al
    Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China.
    J Gastroenterol Hepatol. 2021;36:1326-1333.
    >> Share

  273. TANDON R, Froghi S
    Artificial liver support systems.
    J Gastroenterol Hepatol. 2021;36:1164-1179.
    >> Share

    April 2021
  274. PUDIPEDDI A, Han J, Leong R
    Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign.
    J Gastroenterol Hepatol. 2021 Apr 29. doi: 10.1111/jgh.15510.
    >> Share

  275. KAPURIA D, Bollipo S, Rabiee A, Ben-Yakov G, et al
    Roadmap to resuming care for liver diseases after coronavirus disease-2019.
    J Gastroenterol Hepatol. 2021;36:885-892.
    >> Share

  276. CHRYSAVGIS L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al
    The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:893-909.
    >> Share

  277. SHIGEFUKU R, Iwasa M, Eguchi A, Tamai Y, et al
    Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease.
    J Gastroenterol Hepatol. 2021;36:1006-1014.
    >> Share

    March 2021
  278. SUNG YS, Park B, Park HJ, Lee SS, et al
    Radiomics and deep learning in liver diseases.
    J Gastroenterol Hepatol. 2021;36:561-568.
    >> Share

  279. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
    Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
    J Gastroenterol Hepatol. 2021;36:543-550.
    >> Share

  280. LEE HW, Sung JJY, Ahn SH
    Artificial intelligence in liver disease.
    J Gastroenterol Hepatol. 2021;36:539-542.
    >> Share

    February 2021
  281. VADARLIS A, Antza C, Bakaloudi DR, Doundoulakis I, et al
    Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:311-319.
    >> Share

    January 2021
  282. YOSHINO K, Taura K, Iwaisako K, Masano Y, et al
    A novel mouse model for cholestasis-induced liver fibrosis resolution by cholecystojejunostomy.
    J Gastroenterol Hepatol. 2021 Jan 15. doi: 10.1111/jgh.15406.
    >> Share

  283. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
    Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    J Gastroenterol Hepatol. 2021;36:257-261.
    >> Share

  284. GRONBAEK H, Moller HJ, Saliba F, Zeuzem S, et al
    Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.
    J Gastroenterol Hepatol. 2021;36:240-248.
    >> Share

    October 2020
  285. YANG J, Sontag D, Gong Y, Minuk GY, et al
    Enhanced Gemcitabine Cytotoxicity with Knockdown of Multidrug Resistance Protein Genes in Human Cholangiocarcinoma Cell Lines.
    J Gastroenterol Hepatol. 2020 Oct 1. doi: 10.1111/jgh.15289.
    >> Share

    September 2020
  286. PYO JH, Kim TJ, Lee H, Choi SC, et al
    Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study.
    J Gastroenterol Hepatol. 2020 Sep 4. doi: 10.1111/jgh.15236.
    >> Share

    August 2020
  287. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
    Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
    J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
    >> Share

    July 2020
  288. KIM KS, Kwon HM, Jung KW, Sang BH, et al
    Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant.
    J Gastroenterol Hepatol. 2020 Jul 13. doi: 10.1111/jgh.15179.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016